Therefore, we suggest that, via a similar mechanism, cells with an immunological role depending on the high production of LIGHT and RANKL can take part in the enhanced OC formation supporting bone disease in treated MM patients. The gene discussed is TNFSF11; the disease is Miyoshi myopathy.